Pulse Biosciences Inc Cash Flow-to-Debt Ratio
Pulse Biosciences Inc cash flow-to-debt ratio. Pulse Biosciences Inc (PLSE) has a Cash Flow-to-Debt Ratio of -1.16x as of June 2026, meaning its operating cash flow of $-18.71 Million could theoretically repay -1% of its total liabilities ($16.06 Million) in one year. See Pulse Biosciences Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Pulse Biosciences Inc (2014–2025)
Cash flow-to-debt ratio of Pulse Biosciences Inc from 2014 to 2025. Historical debt coverage capacity for Pulse Biosciences Inc across 12 annual periods. Also explore PLSE net asset momentum to track the company's year-over-year net asset growth rate.
Pulse Biosciences Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Pulse Biosciences Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Pulse Biosciences Inc. For the full cash flow conversion analysis, see PLSE cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.50x | $-54.12 Million | $15.46 Million | ▼ -69.5% |
| 2024 | -2.07x | $-36.34 Million | $17.60 Million | ▲ +7.5% |
| 2023 | -2.23x | $-33.04 Million | $14.79 Million | ▼ -280.6% |
| 2022 | -0.59x | $-47.01 Million | $80.12 Million | ▲ +79.9% |
| 2021 | -2.91x | $-54.10 Million | $18.56 Million | ▼ -51.6% |
| 2020 | -1.92x | $-35.37 Million | $18.40 Million | ▲ +37.1% |
| 2019 | -3.06x | $-34.19 Million | $11.18 Million | ▲ +44.9% |
| 2018 | -5.55x | $-23.90 Million | $4.31 Million | ▼ -91.5% |
| 2017 | -2.90x | $-11.09 Million | $3.83 Million | ▲ +63.4% |
| 2016 | -7.92x | $-8.05 Million | $1.02 Million | ▼ -57.6% |
| 2015 | -5.03x | $-3.32 Million | $659.76K | ▼ -5188.7% |
| 2014 | -0.10x | $-173.14K | $1.82 Million | — |